publication date: Jun. 9, 2017

How drugs go viral: Flatiron’s real-world data show how uptake happens

By Matthew Bin Han Ong

The graphs make it seem so simple:

Doctors learn about a new therapy. They start to prescribe it. A standard of care is born. In a matter of months.

And you can see it all in utilization data compiled by Flatiron Health and made available to The Cancer Letter. Data gleaned from electronic health records of nearly 35,000 cancer patients make it possible to correlate landmark events—presentation, publication, approval—with real-world prescribing patterns.

The data, presented in line graphs published here, show expanding use of targeted agents and immunotherapies over the past two years in the treatment of patients with advanced non-small cell lung cancer and Hodgkin’s disease. The graphs show how physicians rely on clinical trial results immediately after they are presented or published—well before FDA approval.

Flatiron’s dataset focused on utilization of the following drugs:

Nivolumab (Opdivo) and pembrolizumab (Keytruda), programmed death-1 checkpoint inhibitors, in advanced NSCLC patients,

Nivolumab in patients with Hodgkin’s lymphoma, and

Crizotinib (Xalkori), an anaplastic lymphoma kinase and c-ros oncogene-1 inhibitor, in NSCLC patients.

The immediacy of reporting is unprecedented: it’s not a surprise that oncologists use early trial data to guide clinical decision-making prior to FDA approval, but no one has aggregated this information in real time.

Flatiron’s analysis, which relies on data from their collaboration … Continue reading How drugs go viral: Flatiron’s real-world data show how uptake happens

To access this members-only content, please log in.
If you're not a subscriber why not join today?
If you believe you should be able to view this area but cannot log in, then please contact us and we will try to rectify this issue as soon as possible.
To gain access to the members only content click here to subscribe.
You will be given immediate access to premium content on the site.
Click here to join.

Copyright (c) 2017 The Cancer Letter Inc.